Remedy: Confidently toward the earnings leap in Q4

Remedy’s Q3 figures were clearly below our expectations. This was mainly due to timing factors and a reminder of the major fluctuations in the company's business between quarters. In operational terms, Remedy's strategy and game projects have progressed as planned, and the company reiterated with confidence its outlook that anticipates earnings growth for the whole year. Thus, the big picture of the company's growth story remains unchanged and there are clear drivers behind the significant earnings growth expectations that have been built for Q4. In our estimate, Remedy's game projects that are under development will enable the company to take the next significant growth leap in 2023-2024. When looking at these years, we consider the share valuation attractive.